Lea Rossi

Lea Rossi

Auto-generated profile, based on publicly available information

Lea Rossi

Department of Surgical Oncology Centre Leon Berard, Lyon, France

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2017 in Bulletin du Cancer
Verified
Journal Article
Closed access
ABAnne-Sophie Bats
Anne-Sophie Bats
LRLéa Rossi
Léa Rossi
MFMarie-Aude Le Frere-Belda
Marie-Aude Le Frere-Belda
CNCéline Narjoz
Céline Narjoz
CCCaroline Cournou
Caroline Cournou
FLFabrice Lecuru
Fabrice Lecuru

9 January 2021 in Cancers
Verified
Journal Article
Open access
PDF file
KHKhalil Hodroj
Khalil Hodroj
ASAleksandra Stevovic
Aleksandra Stevovic
VAValery Attignon
Valery Attignon
DFDomenico Ferraioli
Domenico Ferraioli
PMPierre Meeus
Pierre Meeus
IRIsabelle Ray-Coquard
Isabelle Ray-Coquard
Most patients with malignant ovarian germ cell tumors (MOGTCs) have a very good prognosis and chemotherapy provides curative treatment; however, patients with yolk sac tumors (OYSTs) have a significantly worse prognosis. OYSTs are rare tumors and promising results are expected with the use of specific therapeutic strategies after the failure of platinum-based first-line and salvage regimens. We initiated a project in collaboration with EORTC SPECTA, to explore the molecular characteristics of OYSTs. The pilot project used retrospective samples from ten OYST relapsed and disease-free patients. Each patient had a molecular analysis performed with FoundationOne CDx describing the following variables according to the Foundation Medicine Incorporation (FMI): alteration type (SNV, deletion), actionable gene alteration, therapies approved in EU (for patient’s tumor type and other tumor types), tumor mutational burden (TMB), and microsatellite instability (MSI) status. A total of 10 patients with OYST diagnosed between 2007 and 2017 had a molecular analysis. A molecular alteration was identified in four patients (40%). A subset of three patients (33.3% of all patients) harbored targetable oncogenic mutations in KRAS, KIT, ARID1A. Two patients at relapse harbored a targetable mutation. This retrospective study identifies clinically relevant molecular alterations for all relapsed patients with molecular analysis. Dedicated studies are needed to demonstrate the efficacy of specific therapeutic strategies after the failure of platinum-based first-line and salvage regimens and to explore the potential relationship of a molecular alteration and patient outcome.

6 March 2025 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
DFDomenico Ferraioli
Domenico Ferraioli
LFLuca Fuso
Luca Fuso
FCFrancesca Chiadó
Francesca Chiadó
CRChiara Russo
Chiara Russo
LRLea Rossi
Lea Rossi
NCNicolas Chopin
Nicolas Chopin

20 June 2023 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
ETEstelle Turrel
Estelle Turrel
NCNicolas Chopin
Nicolas Chopin
PMPierre Meeus
Pierre Meeus
ABAnna Blache
Anna Blache
IRIsabelle Ray-Coquard
Isabelle Ray-Coquard
LRLea Rossi
Lea Rossi

24 February 2022 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
JOJeanne Ouvrier-Neyret
Jeanne Ouvrier-Neyret
LRLéa Rossi
Léa Rossi
VMViolette Mesdag
Violette Mesdag
SKSophie Klingler
Sophie Klingler
CFChristelle Faure
Christelle Faure
MHMELLIE HEINEMANN
MELLIE HEINEMANN

11 December 2025 in Clinical Surgical Oncology
Verified
Journal Article
Open access
NDNavid Mokarram Dorri
Navid Mokarram Dorri
LFLaura Foulhioux
Laura Foulhioux
CZChristophe Zemmour
Christophe Zemmour
QTquentin dominique thomas
quentin dominique thomas
HCHélène Costaz
Hélène Costaz
ELEric Lambaudie
Eric Lambaudie